Genital leiomyoma

Last updated

Genital leiomyomas (also known as dartoic leiomyomas) are leiomyomas that originate in the dartos muscles, or smooth muscles, of the genitalia, areola, and nipple. [1] They are a subtype of cutaneous leiomyomas that affect smooth muscle found in the scrotum, labia, or nipple. They are benign tumors, but may cause pain and discomfort to patients. [2] Genital leiomyoma can be symptomatic or asymptomatic and is dependent on the type of leiomyoma. In most cases, pain in the affected area or region is most common. For vaginal leiomyoma, vaginal bleeding and pain may occur. Uterine leiomyoma may exhibit pain in the area as well as painful bowel movement and/or sexual intercourse. Nipple pain, enlargement, and tenderness can be a symptom of nipple-areolar leiomyomas. Genital leiomyomas can be caused by multiple factors, one can be genetic mutations that affect hormones such as estrogen and progesterone. Moreover, risk factors to the development of genital leiomyomas include age, race, and gender. Ultrasound and imaging procedures are used to diagnose genital leiomyomas, while surgically removing the tumor is the most common treatment of these diseases. Case studies for nipple areolar, scrotal, and uterine leiomyoma were used, since there were not enough secondary resources to provide more evidence.

Contents

Types of genital leiomyomas

Uterine leiomyoma Uterine Fibroids.png
Uterine leiomyoma

Uterine

Uterine leiomyomas are benign tumors that affect 70% of European people with uteri and more than 80% African descent people with uteri by the time they turn 50 years of age. However, only 30% of people with uteri experience symptoms. [3] Of those with uterine leiomyomas, 29% result in hospitalizations. [4] One-third of patients with these fibroids experience life-threatening anemia, a condition where the body does not have enough oxygen due to lack of red blood cells to carry oxygen throughout the body. [5] These tumors are mainly treated by performing hysterectomies, a procedure in which the uterus is removed, and account for approximately 40–60% of all performed hysterectomies. [4] [6] Symptoms are dependent on the location of the tumor, which may occur in the submucosal (under the mucous membranes and lines the inner part of some organs), intramural (within the walls of the organs), or subserosal areas (under the serosa and lines the outer part of some organs).

Nipple-areolar

Nipple-areolar leiomyoma is a rare type of genital leiomyoma. It presents as either unilateral or bilateral growth of benign tumor of the smooth muscle that can be painful, tender, and inflamed. [7] They are typically less than 2 cm in length. [8] Since this is an extremely rare tumor, with only 50 cases reported in literature, it is often only reported to physicians due to chronic nipple pain. [9]

Vaginal

Vaginal paraurethral leiomyoma is another type of genital leiomyoma that is also less common compared to other types of leiomyoma. It presents as a benign tumor of the smooth muscle in the genitourinary tract, which includes urinary and genital organs, that can grow rapidly during pregnancy. On the other hand, the tumor tends to decrease in size upon menopause. This may be due to the growth of tumor that is dependent on hormones. There is not a definite cause for the development of the disease, but one hypothesis is that it originates from a blood vessel tissue and smooth muscle fiber residue in an embryo. Imaging and histopathological examination is used for diagnosis of the disease. Furthermore, treatment of the disease is to surgically remove the tumor. [10]

Vulvar leiomyomas are one the most prominent types of genital leiomyomas. Lesions to the vulva may be up to 15 cm in length and they are reported to be acutely painful. Enlargement of these leiomyomas may occur during pregnancy. [8]

Scrotal

Scrotal leiomyoma is considered to be an extremely rare type of genital leiomyoma. Because leiomyomas in the scrotum are usually painless and grow slowly over time, there is a delay in physician referral, with an average of 6–7 years. Physician referral usually occurs when people notice their testicles growing and getting heavier. [11] A review of 11,000 cases of benign and malignant tumors of the scrotum found 11 cases of scrotal leiomyoma. Scrotal leiomyomas can affect males of any age and race, but are more common in Caucasians from the ages of 40–60. The tumor in the scrotum has an average diameter of 6.4 cm. [12]

Signs and symptoms

People with leiomyoma can be presented as asymptomatic, or having no symptoms. However, some people may experience severe symptoms that can interfere with daily activities. Common symptoms are recurrent pain and pressure in the affected region. [13] People with uterine leiomyoma can experience pain during urination, bowel movements, and sexual intercourse. Other symptoms are abnormal vaginal bleeding and severe menstrual cramps. [14]

Nipple-areolar leiomyomas can affect one or both nipples, presenting with symptoms of nipple tenderness. [7] People with leiomyomas in the scrotum generally notice a growing testicle over a span of multiple years, where it can grow and become heavy to the point of discomfort. Due to the painless and slow, progressive growth of the tumor, the time frame between recognizing the tumor and surgical removal can be anywhere from 2 to 20 years. [11]

Causes

Uterine

Genetics

Development and progression of uterine leiomyomas may be contributed by changes in gene regulation or mutation of genes found to be associated with uterine fibroids. Abnormalities of these genes may initiate the formation or growth of these tumors. [15] Modification of signaling pathways and genes (e.g. CYP1A1 , CYP1b1, and MED12 ) exhibits a correlation with the development and growth of tumors in the uterus. [6]

Hormones

The occurrence of uterine leiomyomas is mostly common during reproductive years. This suggests that the role of ovarian hormones, estrogen and progesterone, is important in the development of this disease. Studies have shown that the development of tumors rely on these hormones and that tumors have shown to affect estrogen metabolism as it can increase the amount both its estrogen and progesterone receptors. [16]

Diet and nutrition

Long-term results suggests that diets that are mostly plant-based, composed of fruits and vegetables, and rich in Vitamin D have a positive effect on the development of diseases, including uterine leiomyomas. However, alcohol, coffee, and red meat may have an effect on the progression or growth of these diseases based on observational and epidemiological studies. [17]

Risk Factors

Uterine

Race

At the age of 35, incidence is reported to be 60% in African-American with-uterus persons and 40% in Caucasian with-uterus persons. By the age of 50, the incidence of uterine fibroids was >80% in African-American with-uterus persons and >70% of Caucasian with-uterus persons. [18]

Recurrence of uterine leiomyomas 4–5 years after removal occurs up to 59% of the time for with-uterus persons of African origin. [19]

Age

People with uteri who delay their first pregnancy past the age of 30 are at a higher risk for uterine fibroids. [20]

Genetic factors

Specific genetic alterations may play a role in the development of uterine leiomyomas. A mutation of a single mesenchymal cell, a stem cell that plays an important role in making and repairing bone, and fat – found in the bone marrow and adipose tissues, with the involvement of progesterone and 17 b-estrodiol – can lead to these fibroids. [21]

Early menarche

Some early studies report early age onset of menstruation increases the risk of developing fibroids. However, the biological mechanism of how this occurs is not well understood and further investigation is needed. [22]

Nipple-areolar

Age

The occurrence of benign tumors of the nipple commonly starts at the age of 20 and peaks around the age of 40 to 50. Growth of nipple-areolar leiomyomas may increase even after menopause. [23]

Diagnosis

There are many ways genital leiomyomas can be diagnosed. Those who have genital leiomyomas can be asymptomatic or symptomatic. Symptoms including but not limited to pelvic pain or abnormal menstrual bleeding are used to assess fibroids. Imaging are often used to detect the presence of fibroids, particularly uterine fibroids. This includes ultrasonography, a procedure that uses high-frequency sound waves to capture tissue and organ images; sonohysterography, a painless procedure similar to ultrasonography to capture images inside the uterus; and hysteroscopy, which examines the inside of the uterus and cervix using a flexible tube called a hysteroscope.   [24]

Treatment

Treatment for genital leiomyomas primarily consists of surgical removal. [25] [26] However, genital leiomyomas typically re-occur and may reappear from 6 weeks to over 15 years post-removal. [8] When managing leiomyomas, radiation treatment should be avoided due to the inducing effect of malignant transformation in the smooth muscle of the tumor. [11]

For uterine leiomyomas, complete removal of the uterus is required. [27] There is minimal evidence to support the use of myomectomy to preserve fertility. [28] Evidence shows that preoperative use of gonadotropin-releasing hormone agonists, which prevents or lessen the production of hormones like progesterone, estrogen, and testosterone, can reduce surgical complications. [29]

Subareolar leiomyomas require surgical removals. Precise surgical margins are needed to prevent re-occurrences. [30]

Leiomyomas in the scrotum require an orchidectomy, or surgical removal of one or two testicles.

To manage pain that arises from the fibroids, drugs that affect smooth muscle contraction such as nitroglycerin, nifedipine, phenoxybenzamine and doxazosin can be employed to ease the pain. For nerve pain or tenderness, gabapentin and topical analgesics may be employed. [8]

Clinical cases

Nipple-areolar leiomyomas

41-year-old male

A 41-year-old male presented with a yellow nodule in the upper left areola. He reported mild pain and itching, but denied other symptoms. Sebaceous glands, epidermal hyperplasia, and tumor nests were among the numerous findings that preceded a diagnosis of diagnosis of areolar leiomyoma with sebaceous hyperplasia. Characteristics of the leiomyoma included positive for estrogen and progesterone receptors and high expression of epidermal growth factor, insulin-like growth factor 1, and fibroblast growth factor-2. It is suspected that these growth factors led to the growth of the leiomyoma through an autocrine process. The patient declined resection and the region has remained stable since. [31]

67-year-old female

A 67-year-old female presented with a growing mass on the left breast areolar region. The patient had been taking methotrexate to treat her rheumatoid arthritis. Magnetic resonance imaging led to a conclusion that the tumor arose from the areola. A biopsy led to a diagnosis of diffuse large, non-GC B-cell lymphoma that was suspected to be associated with methotrexate. The tumor reduced in size following the withdrawal of methotrexate. Three months later, another tumor developed in the areolar region of the opposite breast. [32]

35-year-old female

A 35-year-old female presented with a painful lump in the right nipple. The patient reported the lump occurred after a breastfeeding injury three years prior to coming into the outpatient center. The tumor has been growing ever since. A biopsy was performed to confirm the leiomyoma in the nipple. [9]

Uterine leiomyomas

48-year-old female

A 48-year-old-female presented with several uterine fibroids that were asymptomatic. The tumor was removed vaginally and was revealed to be a vaginal leiomyoma. Vaginal leiomyomas are rare and removal by vaginal route is the preferred treatment option. [33]

Scrotal leiomyomas

39-year-old male

A 39-year-old male presented with a dull aching pain in the right scrotum. The patient had a history of his right scrotum slowly growing for the past year. There were no other symptoms of urinary tract infections (UTIs), cough, fever, weight loss, or night sweats. Further examination and an ultrasound scan found a firm mass in the right scrotum with a size of 6 cm x 4 cm that was inseparable from the testis. The patient underwent a right radical orchiectomy, or a surgical operation to remove the one or more testicles, since malignancy of the tumor could not be determined. The patient recovered and was discharged home after the operation. [12]

71-year-old male

A 71-year-old male presented with a large and heavy left scrotum that has been growing for 10 years. Further examination confirmed a firm tumor in the left scrotum that was attached to the testis. The tumor was measured to be 11 cm in diameter. The patient underwent orchidectomy, or surgical removal of the testicle. [11]

See also

Related Research Articles

<span class="mw-page-title-main">Hysterectomy</span> Surgical removal of the uterus

Hysterectomy is the surgical removal of the uterus and cervix. Supracervical hysterectomy refers to removal of the uterus while the cervix is spared. These procedures may also involve removal of the ovaries (oophorectomy), fallopian tubes (salpingectomy), and other surrounding structures. The term “partial” or “total” hysterectomy are lay-terms that incorrectly describe the addition or omission of oophorectomy at the time of hysterectomy. These procedures are usually performed by a gynecologist. Removal of the uterus renders the patient unable to bear children and has surgical risks as well as long-term effects, so the surgery is normally recommended only when other treatment options are not available or have failed. It is the second most commonly performed gynecological surgical procedure, after cesarean section, in the United States. Nearly 68 percent were performed for conditions such as endometriosis, irregular bleeding, and uterine fibroids. It is expected that the frequency of hysterectomies for non-malignant indications will continue to fall given the development of alternative treatment options.

<span class="mw-page-title-main">Uterine cancer</span> Medical condition

Uterine cancer, also known as womb cancer, includes two types of cancer that develop from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus, and uterine sarcoma forms from the muscles or support tissue of the uterus. Endometrial cancer accounts for approximately 90% of all uterine cancers in the United States. Symptoms of endometrial cancer include changes in vaginal bleeding or pain in the pelvis. Symptoms of uterine sarcoma include unusual vaginal bleeding or a mass in the vagina.

Gender-affirming surgery for female-to-male transgender people includes a variety of surgical procedures that alter anatomical traits to provide physical traits more comfortable to the trans man's male identity and functioning.

Heavy menstrual bleeding (HMB), previously known as menorrhagia or hematomunia, is a menstrual period with excessively heavy flow. It is a type of abnormal uterine bleeding (AUB).

<span class="mw-page-title-main">Leiomyoma</span> Medical condition

A leiomyoma, also known as a fibroid, is a benign smooth muscle tumor that very rarely becomes cancer (0.1%). They can occur in any organ, but the most common forms occur in the uterus, small bowel, and the esophagus. Polycythemia may occur due to increased erythropoietin production as part of a paraneoplastic syndrome.

<span class="mw-page-title-main">Adenomyosis</span> Extension of endometrial tissue into the myometrium

Adenomyosis is a medical condition characterized by the growth of cells that proliferate on the inside of the uterus (endometrium) atypically located among the cells of the uterine wall (myometrium), as a result, thickening of the uterus occurs. As well as being misplaced in patients with this condition, endometrial tissue is completely functional. The tissue thickens, sheds and bleeds during every menstrual cycle.

<span class="mw-page-title-main">Vaginal bleeding</span> Medical condition

Vaginal bleeding is any expulsion of blood from the vagina. This bleeding may originate from the uterus, vaginal wall, or cervix. Generally, it is either part of a normal menstrual cycle or is caused by hormonal or other problems of the reproductive system, such as abnormal uterine bleeding.

<span class="mw-page-title-main">Endometrial polyp</span> Mass on the interior lining of the uterus

An endometrial polyp or uterine polyp is a mass in the inner lining of the uterus. They may have a large flat base (sessile) or be attached to the uterus by an elongated pedicle (pedunculated). Pedunculated polyps are more common than sessile ones. They range in size from a few millimeters to several centimeters. If pedunculated, they can protrude through the cervix into the vagina. Small blood vessels may be present, particularly in large polyps.

<span class="mw-page-title-main">Uterine fibroid</span> Medical condition with benign tumors of uterus

Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the uterus, part of the female reproductive system. Some women with fibroids have no symptoms while others may have painful or heavy periods. If large enough, they may push on the bladder, causing a frequent need to urinate. They may also cause pain during penetrative sex or lower back pain. A woman can have one uterine fibroid or many. It is uncommon but possible that fibroids may make it difficult to become pregnant.

<span class="mw-page-title-main">Uterine myomectomy</span> Surgical removal of uterine fibroid

Myomectomy, sometimes also called fibroidectomy, refers to the surgical removal of uterine leiomyomas, also known as fibroids. In contrast to a hysterectomy, the uterus remains preserved and the woman retains her reproductive potential. It still may impact hormonal regulation and the menstrual cycle.

<span class="mw-page-title-main">Uterine artery embolization</span>

Uterine artery embolization is a procedure in which an interventional radiologist uses a catheter to deliver small particles that block the blood supply to the uterine body. The procedure is primarily done for the treatment of uterine fibroids and adenomyosis. Since uterine fibroids are the most common indication, it is also often referred to as uterine fibroid embolization. Compared to surgical treatment for fibroids such as a hysterectomy, in which a woman's uterus is removed, uterine artery embolization may be beneficial in women who wish to retain their uterus. Other reasons for uterine artery embolization are postpartum hemorrhage and uterine arteriovenous malformations.

Intermenstrual bleeding (IMB) is vaginal bleeding at irregular intervals between expected menstrual periods. It may be associated with bleeding with sexual intercourse.

Adenomyoma is a tumor (-oma) including components derived from glands (adeno-) and muscle (-my-). It is a type of complex and mixed tumor, and several variants have been described in the medical literature. Uterine adenomyoma, the localized form of uterine adenomyosis, is a tumor composed of endometrial gland tissue and smooth muscle in the myometrium. Adenomyomas containing endometrial glands are also found outside of the uterus, most commonly on the uterine adnexa but can also develop at distant sites outside of the pelvis. Gallbladder adenomyoma, the localized form of adenomyomatosis, is a polypoid tumor in the gallbladder composed of hyperplastic mucosal epithelium and muscularis propria.

<span class="mw-page-title-main">Menstrual disorder</span> Medical condition affecting menstrual cycle

A menstrual disorder is characterized as any abnormal condition with regards to a woman's menstrual cycle. There are many different types of menstrual disorders that vary with signs and symptoms, including pain during menstruation, heavy bleeding, or absence of menstruation. Normal variations can occur in menstrual patterns but generally menstrual disorders can also include periods that come sooner than 21 days apart, more than 3 months apart, or last more than 10 days in duration. Variations of the menstrual cycle are mainly caused by the immaturity of the hypothalamic-pituitary-ovarian (HPO) axis, and early detection and management is required in order to minimize the possibility of complications regarding future reproductive ability.

The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective tissue of the uterus. They can be difficult to detect, as symptoms are common to other uterine conditions and no specific screening test has been developed. This presents an issue for treatment, as the cancer spreads quickly.

Female genital disease is a disorder of the structure or function of the female reproductive system that has a known cause and a distinctive group of symptoms, signs, or anatomical changes. The female reproductive system consists of the ovaries, fallopian tubes, uterus, vagina, and vulva. Female genital diseases can be classified by affected location or by type of disease, such as malformation, inflammation, or infection.

<span class="mw-page-title-main">Endometrioma</span> Medical condition

Endometrioma is the presence of tissue similar to, but distinct from, the endometrium in and sometimes on the ovary. It is the most common form of endometriosis. Endometrioma is found in 17–44% patients with endometriosis.

<span class="mw-page-title-main">Hereditary leiomyomatosis and renal cell cancer syndrome</span> Medical condition

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) or Reed's syndrome is rare autosomal dominant disorder associated with benign smooth muscle tumors and an increased risk of renal cell carcinoma. It is characterised by multiple cutaneous leiomyomas and, in women, uterine leiomyomas. It predisposes individuals to renal cell cancer, an association denominated hereditary leiomyomatosis and renal cell cancer. It is also associated with increased risk of uterine leiomyosarcoma. The syndrome is caused by a mutation in the fumarate hydratase gene, which leads to an accumulation of fumarate. The inheritance pattern is autosomal dominant and screening can typically begin in childhood.

Elagolix/estradiol/norethisterone acetate, sold under the brand name Oriahnn, is a fixed-dose combination medication used to treat heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It contains elagolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethisterone acetate, a progestin. It is taken by mouth. Oriahnn is co-packaged as a combination of elagolix/estradiol/norethisterone acetate capsules with elagolix capsules.

<span class="mw-page-title-main">Cutaneous leiomyoma</span> Medical condition

Cutaneous leiomyoma, also known as leiomyoma cutis, or cutaneous leiomyomata, is a benign skin tumor made of smooth muscle cells. There are three different types of cutaneous leiomyomas, genital leiomyomas, angioleiomyomas, and piloleiomyomas. Cutaneous leiomyomas can occur sporadically or as a part of a genetic condition. Cutaneous leiomyomas are diagnosed by histopathology and treated by surgical excision.

References

  1. Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). Page 1033. McGraw-Hill. ISBN   0-07-138076-0.
  2. Bernett CN, Mammino JJ (2022). "Cutaneous Leiomyomas". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   29489175 . Retrieved 2022-07-31.
  3. Lewis TD, Malik M, Britten J, San Pablo AM, Catherino WH (2018). "A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma". BioMed Research International. 2018: 2414609. doi: 10.1155/2018/2414609 . PMC   5893007 . PMID   29780819.
  4. 1 2 Merrill RM (January 2008). "Hysterectomy surveillance in the United States, 1997 through 2005". Medical Science Monitor. 14 (1): CR24–CR31. PMID   18160941.
  5. Bartels CB, Cayton KC, Chuong FS, Holthouser K, Arian SE, Abraham T, Segars JH (March 2016). "An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review". Clinical Obstetrics and Gynecology. 59 (1): 30–52. doi:10.1097/GRF.0000000000000171. PMID   26756261. S2CID   10329880.
  6. 1 2 Mathew RP, Francis S, Jayaram V, Anvarsadath S (October 2021). "Uterine leiomyomas revisited with review of literature". Abdominal Radiology. 46 (10): 4908–4926. doi:10.1007/s00261-021-03126-4. PMID   34057564. S2CID   235250560.
  7. 1 2 Chiorean A, Pintican RM, Szep M, Feier D, Rogojan L, Fetica B, et al. (August 2020). "Nipple Ultrasound: A Pictorial Essay". Korean Journal of Radiology. 21 (8): 955–966. doi:10.3348/kjr.2019.0831. PMC   7369201 . PMID   32677380.
  8. 1 2 3 4 Malik K, Patel P, Chen J, Khachemoune A (February 2015). "Leiomyoma cutis: a focused review on presentation, management, and association with malignancy". American Journal of Clinical Dermatology. 16 (1): 35–46. doi:10.1007/s40257-015-0112-1. PMID   25605645. S2CID   207482309.
  9. 1 2 Spyropoulou GA, Pavlidis L, Trakatelli M, Athanasiou E, Pazarli E, Sotiriadis D, Demiri E (January 2015). "Rare benign tumours of the nipple". Journal of the European Academy of Dermatology and Venereology. 29 (1): 7–13. doi:10.1111/jdv.12623. PMID   25124255. S2CID   25298700.
  10. Braga A, Soave I, Caccia G, Regusci L, Ruggeri G, Pitaku I, et al. (June 2021). "What is this vaginal bulge? An atypical case of vaginal paraurethral leiomyoma. A case report and literature systematic review". Journal of Gynecology Obstetrics and Human Reproduction. 50 (6): 101822. doi:10.1016/j.jogoh.2020.101822. PMID   32492525. S2CID   219315417.
  11. 1 2 3 4 Ariafar A, Soltani M, Khajeh F, Zeighami S, Naghdi Sedeh N, Miladpour B (September 2020). "Scrotal leiomyoma a rare benign intra-scrotal mass could lead to unnecessary orchiectomy". Urology Case Reports. 32: 101170. doi:10.1016/j.eucr.2020.101170. PMC   7184519 . PMID   32368497.
  12. 1 2 Egharevba PA, Omoseebi O, Okunlola AI, Omisanjo OA (2020). "Scrotal leiomyoma: a rare cause of scrotal swelling". African Journal of Urology. 26 (1): 72. doi: 10.1186/s12301-020-00082-1 . ISSN   1961-9987. S2CID   227121985.
  13. Florence AM, Fatehi M (2022). "Leiomyoma". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   30855861 . Retrieved 25 July 2022.
  14. Costantini E, Cochetti G, Porena M (August 2008). "Vaginal para-urethral myxoid leiomyoma: case report and review of the literature". International Urogynecology Journal and Pelvic Floor Dysfunction. 19 (8): 1183–1185. doi:10.1007/s00192-008-0588-9. PMID   18351279. S2CID   40050485.
  15. Medikare V, Kandukuri LR, Ananthapur V, Deenadayal M, Nallari P (July 2011). "The genetic bases of uterine fibroids; a review". Journal of Reproduction & Infertility. 12 (3): 181–191. PMC   3719293 . PMID   23926501.
  16. Cook JD, Walker CL (May 2004). "Treatment strategies for uterine leiomyoma: the role of hormonal modulation". Seminars in Reproductive Medicine (in German). 22 (2): 105–111. doi:10.1055/s-2004-828616. PMID   15164305. S2CID   260320953.
  17. Afrin S, AlAshqar A, El Sabeh M, Miyashita-Ishiwata M, Reschke L, Brennan JT, et al. (May 2021). "Diet and Nutrition in Gynecological Disorders: A Focus on Clinical Studies". Nutrients. 13 (6): 1747. doi: 10.3390/nu13061747 . PMC   8224039 . PMID   34063835.
  18. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM (January 2003). "High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence". American Journal of Obstetrics and Gynecology. 188 (1): 100–107. doi:10.1067/mob.2003.99. PMID   12548202.
  19. Donnez J, Dolmans MM (November 2016). "Uterine fibroid management: from the present to the future". Human Reproduction Update. 22 (6): 665–686. doi:10.1093/humupd/dmw023. PMC   5853598 . PMID   27466209.
  20. Petraglia F, Serour GI, Chapron C (December 2013). "The changing prevalence of infertility". International Journal of Gynaecology and Obstetrics. 123 (Suppl 2): S4–S8. doi: 10.1016/j.ijgo.2013.09.005 . PMID   24112745. S2CID   45271567.
  21. Hattori T, Singh VK, McGeer EG, McGeer PL (January 1976). "Immunohistochemical localization of choline acetyltransferase containing neostriatal neurons and their relationship with dopaminergic synapses". Brain Research. 102 (1): 164–173. doi:10.1016/0006-8993(76)90583-7. PMID   2366. S2CID   1071780.
  22. Khan AT, Shehmar M, Gupta JK (2014). "Uterine fibroids: current perspectives". International Journal of Women's Health. 6: 95–114. doi: 10.2147/IJWH.S51083 . PMC   3914832 . PMID   24511243.
  23. Spyropoulou GA, Pavlidis L, Trakatelli M, Athanasiou E, Pazarli E, Sotiriadis D, Demiri E (January 2015). "Rare benign tumours of the nipple". Journal of the European Academy of Dermatology and Venereology. 29 (1): 7–13. doi:10.1111/jdv.12623. PMID   25124255. S2CID   25298700.
  24. De La Cruz MS, Buchanan EM (January 2017). "Uterine Fibroids: Diagnosis and Treatment". American Family Physician. 95 (2): 100–107. PMID   28084714.
  25. Rakotomahenina H, Rajaonarison J, Wong L, Brun JL (August 2017). "Myomectomy: technique and current indications". Minerva Ginecologica. 69 (4): 357–369. doi:10.23736/S0026-4784.17.04073-4. PMID   28447445.
  26. Sabry M, Al-Hendy A (April 2012). "Medical treatment of uterine leiomyoma". Reproductive Sciences. 19 (4): 339–353. doi:10.1177/1933719111432867. PMC   3343067 . PMID   22378865.
  27. Juhasz-Böss I, Gabriel L, Bohle RM, Horn LC, Solomayer EF, Breitbach GP (2018). "Uterine Leiomyosarcoma". Oncology Research and Treatment. 41 (11): 680–686. doi: 10.1159/000494299 . PMID   30321869. S2CID   53114823.
  28. Metwally M, Raybould G, Cheong YC, Horne AW (January 2020). "Surgical treatment of fibroids for subfertility". The Cochrane Database of Systematic Reviews. 1 (1): CD003857. doi:10.1002/14651858.CD003857.pub4. PMC   6989141 . PMID   31995657.
  29. Lethaby A, Puscasiu L, Vollenhoven B (November 2017). "Preoperative medical therapy before surgery for uterine fibroids". The Cochrane Database of Systematic Reviews. 2017 (11): CD000547. doi:10.1002/14651858.CD000547.pub2. PMC   6486044 . PMID   29139105.
  30. Salemis NS (November 2020). "Subareolar male genital leiomyoma: An exceedingly rare clinical entity". The Breast Journal. 26 (11): 2248–2249. doi: 10.1111/tbj.14052 . PMID   32935434. S2CID   221748592.
  31. Oya K, Nakamura Y, Fujisawa Y (2022). "Unilateral areolar leiomyoma with sebaceous hyperplasia". Indian Journal of Dermatology, Venereology and Leprology. 88 (4): 536–540. doi: 10.25259/IJDVL_7_2020 . PMID   35593282. S2CID   248713094.
  32. Matsubayashi RN, Iwasaki H, Iwakuma N, Momosaki S (2019). "Methotrexate (MTX)-associated malignant lymphoma of the bilateral breast: imaging features in comparison to other nipple-areolar tumors". Clinical Imaging. 53: 120–125. doi:10.1016/j.clinimag.2018.10.004. PMID   30340074. S2CID   53008893.
  33. Shah M, Saha R, Kc N (May 2021). "Vaginal Leiomyoma: A Case Report". Journal of Nepal Medical Association. 59 (237): 504–505. doi:10.31729/jnma.6180. PMC   8673445 . PMID   34508428.